TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.06 USD
-0.25 (-10.82%)
Updated Sep 23, 2024 01:47 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for TFF Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 32 | 32 | 19 | 12 |
Income After Depreciation & Amortization | -22 | -32 | -32 | -19 | -12 |
Non-Operating Income | 1 | 0 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -21 | -32 | -31 | -19 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -32 | -31 | -19 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -32 | -31 | -19 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -31 | -32 | -19 | -12 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -22 | -32 | -32 | -19 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.79 | NA | 0.99 | 0.82 | 0.28 |
Diluted EPS Before Non-Recurring Items | -11.85 | NA | -31.25 | -22.75 | -132.75 |
Diluted Net EPS (GAAP) | -11.85 | -26.50 | -31.25 | -22.75 | -132.75 |
Fiscal Year end for TFF Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.65 | 0.20 | 0.11 | 0.23 | 0.33 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.65 | 0.20 | 0.11 | 0.23 | 0.33 |
SG&A, R&D, and Dept/Amort Expenses | 4.61 | 6.00 | 5.48 | 4.66 | 5.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.96 | -5.80 | -5.37 | -4.43 | -5.02 |
Non-Operating Income | -0.52 | 0.06 | 0.61 | 0.01 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.48 | -5.74 | -4.76 | -4.41 | -5.02 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.48 | -5.74 | -4.76 | -4.41 | -5.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.48 | -5.74 | -4.76 | -4.41 | -5.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.67 | 2.39 | 2.37 | 1.90 | 1.45 |
Diluted EPS Before Non-Recurring Items | -1.22 | -2.40 | -2.01 | -2.25 | -3.50 |
Diluted Net EPS (GAAP) | -1.22 | -2.40 | -1.35 | -2.25 | -3.50 |